# Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

> **NCT00303836** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 58 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **PROCEDURE:** in vitro-treated peripheral blood stem cell transplantation
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** MART-1 antigen
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** aldesleukin

## Key facts

- **NCT ID:** NCT00303836
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2013-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303836, "Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00303836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*